Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AACR poster VP_2014

98 views

Published on

  • Be the first to comment

  • Be the first to like this

AACR poster VP_2014

  1. 1. Prostate Cancer Immunotherapy Development Using Tumor-specific CAR Design Victor Prima*, Sergei Kusmartsev* and Johannes Vieweg Department of Urology, College of Medicine, University of Florida, Gainesville, FL ABSTRACT Prostate cancer that has progressed to metastatic disease remains largely untreatable. One of the most promising modalities for treatment of advanced cancer is immunotherapy based on adoptive transfer of T lymphocytes. It was demonstrated that T lymphocytes expressing tumor-specific chimeric artificial receptor (CAR) exert potent anti-tumor activity upon adoptive transfer into tumor-bearing host. Recent studies identified Prostate-specific membrane antigen (PSMA) and ligands for NK cell –activating receptors (e.g. NKG2D ligands) as the targets primarily expressed on tumor cells but absent on most normal tissues. We generated two sets of chimeric DNA constructs: CAR-PSMA and CAR-NKG2D, that can be used for transduction of human T cells. Both of them consist of an antigen-recognizing domain bound to the transmembrane and intracellular domains of various signal-transducing and/or cell-activating molecules and a signaling molecule. Extracellular antigen-recognizing domain of CAR-PSMA consists of single chain anti-PSMA antibody (scFv) while in another construct set it is human NKG2D receptor. Intracellular CD3 ξ- chain functions as a signaling molecule triggering T-cell activation. Co-stimulatory proteins CD28, CD40L or OX40L which can compensate for the lack of co-stimulation from the target tumor cell are either fused to CD3 ξ-chain as intracellular domains or are expressed on cell surface from bi-cistronic constructs. Upon transduction of human T cells with these constructs, transduced cells presented surface expression of the chimeric scFv anti-PSMA or NKG2D, respectively. In vitro experiments demonstrated specific binding activity and cytotoxicity of human T lymphocytes expressing anti-PSMA or NKG2D CARs against prostate cancer cells which creates the basis for a viable prostate cancer immunotherapy development. *VP and SK contributed equally to the project. The authors would like to thank Galante Foundation for the generous support. Generation of chimeric DNA constructs encoding human TCR signaling domains. The specific cDNA sequences employed in our constructs incorporate various domains of human T and NK cell receptor signaling fused to the CD3ξ chain at the 3’-end (Fig.2). Original full-lengths human cDNA clones were obtained from NIH Mammalian Gene Collection (MGC). Following functional domain analysis and oligonucleotide design the In-Fusion system of DNA cloning (Clontech) was used to assemble the CAR constructs. Generation of CD3-CD28-anti-PSMA DNA construct. In order to engineer the T cells that express receptor specific for human prostate-specific membrane antigen (PSMA) we used the strategy of consecutive CAR constructs assembling (Fig.3). cDNA sequences encoding the human CD28 and CD3ξ chains were linked to variable domains of anti-PSMA antibody (scFv) derived from the J415 hybridoma (ATCC) (Fig.4). In this chimeric anti-PSMA receptor the scFv serves as an extracellular antigen-binding domain, CD28 domain stimulates cell proliferation and cytokine expression, and CD3ξ chain is the intracellular signaling module activating T cell upon antigen engagement. Transgene expression here is driven by a composite promoter consisting of CMV enhancer/modified beta-actin promoter – CBA (Fig.5). Generation of CD3-NKG2D DNA construct. To generate T cells with ability to kill NKG2D-ligand–bearing tumor cells, cDNA sequences encoding the human NKG2D receptor and CD3ξ chain were assembled to make the chimeric NKG2D receptor. NKG2D is a type II protein, in which the N-terminus is located intracellularly whereas the CD3ξ chain is a type I protein with the C-terminus in the cytoplasm. To create an NKG2D-CD3ξ fusion protein, the initiation codon ATG was placed ahead of the cDNA encoding the cytoplasmic region of the CD3ξ chain followed by wild-type NKG2D cDNA. Upon expression, the orientation of the CD3ξ domain is reversed inside the cells. The extracellular domain derived from NKG2D serves as antigen-binding part of the receptor, and CD3ξ chain is the intracellular signaling module activating T cell upon antigen engagement. The schematic maps of the expression constructs generated for assessment of functional roles of NKG2D and PSMA CARs are shown in Fig.5. The CAR-expressing retroviruses were produced using standard molecular techniques. Functionality of cell transduction techniques and transgene expression was assessed with HEK-293 and Jurkat cells as modeling cell lines. Our data show successful retroviral delivery of the chimeric constructs with high level of ectopic expression both in the modeling cell lines (Fig.6) and in the T cells (Fig.10, 11). Specific binding activity of anti-tumor CARs. Assays for the ability of CAR- transduced T cells to bind the target cells expressing PSMA or/and NKG2D ligands on their surface confirmed specificity of this interaction (Fig.7 as an example). Cytotoxic T lymphocytes (CTL) activity On day 7-8 after infection with CAR RV or control RV (mock) cultured T cells were collected, washed with PBS and mixed with tumor cells at cell ratios 10:1 or 25:1 in complete RPMI-1640 medium in 96 well plates. Cell mixtures were cultured at 370 C in humidified CO2 incubator for twenty hours. CTL activity was measured using LDH cytotoxicity assay (Sigma-Aldrich) according to the manufacturer’s protocol. The preliminary data of in vitro tests indicate cytotoxicity of human T lymphocytes expressing anti-PSMA or NKG2D CARs against the cells expressing cancer-related ligands (Fig.8). EXPERIMENTAL APPROACH CONCLUSIONS We generated two sets of chimeric DNA constructs: CAR-PSMA and CAR-NKG2D, consisting of an antigen-recognizing domain and various domains of T and NK cell receptor signaling fused to the CD3ξ. Upon viral transduction of human T cells with these constructs, transduced cells presented significant surface expression of the chimeric scFv anti-PSMA or NKG2D, respectively. Binding specificity and cytotoxicity of human T lymphocytes expressing recombinant anti-PSMA or NKG2D CARs make feasible the development of effective immunotherapy against prostate cancer.

×